
        <html>
            <head>
                <link rel='stylesheet' href='https://cdn.jsdelivr.net/gh/kognise/water.css@1.2.1/dist/light.css' />
            </head>
            <body>
                <h1>source data for table 1 (6)</h1>
    <br><h2><a href="https://github.com/elifesciences/elife-article-xml/tree/master/articles/elife-26129-v3.xml">elife-26129-v3.xml</a></h2><table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.26129.015</object-id><label>Table 1.</label><caption><title>Summary of FXR1-knockdown-induced anti-proliferation in cancer cell lines and CRISPR-Cas9-engineered cell clones.</title><p>The cell line or CRISPR clone name, cancer type, <italic>TP53</italic> and <italic>FXR2</italic> copy number alteration (based on the&#160;CCLE database or knockout confirmation), FXR1-sh3 knockdown (KD) efficiency (determined&#160;by q-RT-PCR and WB), and FXR1 KD-induced anti-proliferation efficiency are listed. Dark green, anti-proliferation efficiency&#160;&gt;60%. Yellow green, anti-proliferation 30&#8211;60%. Yellow, anti-proliferation&#160;&lt;30%. Data of KD efficiency and anti-proliferation efficiency represent means of at least three independent experiments. Del, deletion; WT, copy number normal; KO, knockout.</p><p><supplementary-material id="table1sdata1"><object-id pub-id-type="doi">10.7554/eLife.26129.016</object-id><label>Table 1&#8212;source data 1.</label><caption><title>Source data for <xref ref-type="table" rid="table1">Table 1</xref>.</title></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-26129-table1-data1-v3.xls"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Cell</th><th>Cancer</th><th><italic>TP53</italic></th><th><italic>FXR2</italic></th><th>FXR1 KD efficiency (%)</th><th>FXR1 KD induced anti-proliferation (%)</th></tr></thead><tbody><tr><td rowspan="13">Cancer cell line</td><td>HL-60</td><td>Acute myeloid leukemia</td><td><bold>Del</bold></td><td><bold>Del</bold></td><td>77.6</td><td>73.4</td></tr><tr><td>KATOIII</td><td>Gastric</td><td><bold>Del</bold></td><td><bold>Del</bold></td><td>83.5</td><td>76.4</td></tr><tr><td>KMS-11</td><td>Multiple myeloma</td><td><bold>Del</bold></td><td><bold>Del</bold></td><td>95.7</td><td>88.3</td></tr><tr><td>H358</td><td>Lung</td><td><bold>Del</bold></td><td><bold>Del</bold></td><td>79.9</td><td>95.3</td></tr><tr><td>H1299</td><td>Lung</td><td><bold>Del</bold></td><td>WT</td><td>96.4</td><td>&#8722;1.1</td></tr><tr><td>L540</td><td>Hodgkin lymphoma</td><td><bold>Del</bold></td><td>WT</td><td>94.9</td><td>&#8722;5.8</td></tr><tr><td>MG-63</td><td>Osteosarcoma</td><td><bold>Del</bold></td><td>WT</td><td>96.8</td><td>&#8722;4.5</td></tr><tr><td>SKOV3</td><td>Ovarian</td><td><bold>Del</bold></td><td>WT</td><td>89.0</td><td>&#8722;7.3</td></tr><tr><td>Hep3B</td><td>Liver</td><td>WT</td><td><bold>Del</bold></td><td>94.0</td><td valign="bottom">&#8722;0.8</td></tr><tr><td>A549</td><td>Lung</td><td>WT</td><td>WT</td><td>72.7</td><td>15.5</td></tr><tr><td>AGS</td><td>Gastric</td><td>WT</td><td>WT</td><td>73.6</td><td>12.8</td></tr><tr><td>HepG2</td><td>Liver</td><td>WT</td><td>WT</td><td>92.0</td><td>2.8</td></tr><tr><td>MKN45</td><td>Gastric</td><td>WT</td><td>WT</td><td>71.5</td><td>3.4</td></tr><tr><td rowspan="15">CRISPR-Cas9 KO clone</td><td>DKO1</td><td>Gastric</td><td>WT</td><td>WT</td><td>88.8</td><td>1.9</td></tr><tr><td>DKO5</td><td>Gastric</td><td>WT</td><td>WT</td><td>86.0</td><td>2.7</td></tr><tr><td>DKO11</td><td>Gastric</td><td><bold>KO</bold></td><td><bold>KO</bold></td><td>79.0</td><td>49.8</td></tr><tr><td>DKOL7-1</td><td>Gastric</td><td><bold>KO</bold></td><td><bold>KO</bold></td><td>92.0</td><td>68.5</td></tr><tr><td>DKOL7-3</td><td>Gastric</td><td><bold>KO</bold></td><td><bold>KO</bold></td><td>87.5</td><td>45.3</td></tr><tr><td>FXR2 KO10</td><td>Gastric</td><td>WT</td><td>WT</td><td>80.6</td><td>34.1</td></tr><tr><td>FXR2 KO11</td><td>Gastric</td><td>WT</td><td>WT</td><td>75.8</td><td>19.0</td></tr><tr><td>FXR2 KO17</td><td>Gastric</td><td>WT</td><td>WT</td><td>77.2</td><td>6.8</td></tr><tr><td>FXR2 KO5</td><td>Gastric</td><td>WT</td><td><bold>KO</bold></td><td>81.3</td><td>16.2</td></tr><tr><td>FXR2 KO16</td><td>Gastric</td><td>WT</td><td><bold>KO</bold></td><td>72.9</td><td>15.6</td></tr><tr><td>TP53 KO3-3</td><td>Gastric</td><td>WT</td><td>WT</td><td>51.1</td><td>&#8722;5.3</td></tr><tr><td>TP53 KO3-10</td><td>Gastric</td><td>WT</td><td>WT</td><td>92.9</td><td>&#8722;5.8</td></tr><tr><td>TP53 KO3-6-1</td><td>Gastric</td><td><bold>KO</bold></td><td>WT</td><td>85.3</td><td>34.0</td></tr><tr><td>TP53 KO3-6-2</td><td>Gastric</td><td><bold>KO</bold></td><td>WT</td><td>81.4</td><td>&#8722;5.3</td></tr><tr><td>TP53 KO3-14-6</td><td>Gastric</td><td><bold>KO</bold></td><td>WT</td><td>86.2</td><td>12.5</td></tr></tbody></table></table-wrap><br><h2><a href="https://github.com/elifesciences/elife-article-xml/tree/master/articles/elife-31549-v1.xml">elife-31549-v1.xml</a></h2><table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.31549.006</object-id><label>Table 1.</label><caption><title>Baseline characteristics of the participants included in analysis.</title><p><supplementary-material id="table1sdata1"><object-id pub-id-type="doi">10.7554/eLife.31549.007</object-id><label>Table 1&#8212;source data 1.</label><caption><title>Source data for <xref ref-type="table" rid="table1">Table 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-31549-table1-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th valign="top"/><th valign="top">LD-SP/SP</th><th valign="top">LD-SP/PIP</th><th valign="top">LD-PIP/PIP</th><th valign="top">LD-PIP/SP</th></tr></thead><tbody><tr><td valign="top">No. subjects</td><td valign="top"/><td valign="top">n&#160;=&#160;4</td><td valign="top">n&#160;=&#160;4</td><td valign="top">n&#160;=&#160;4</td><td valign="top">n&#160;=&#160;4</td></tr><tr><td valign="top">Treatment 1 (T1)</td><td/><td valign="top">Sulfadoxine-pyrimethamine 500 mg/25 mg</td><td valign="top">Sulfadoxine-pyrimethamine 500 mg/25 mg</td><td valign="top">Piperaquine 480 mg</td><td valign="top">Piperaquine 480 mg</td></tr><tr><td valign="top">Treatment 2 (T2)</td><td/><td valign="top">Sulfadoxine-pyrimethamine 1000 mg/50 mg</td><td valign="top">Piperaquine 960 mg</td><td valign="top">Piperaquine 960 mg</td><td valign="top">Sulfadoxine-pyrimethamine 1000 mg/50 mg</td></tr><tr><td valign="top">Sex</td><td/><td/><td/><td/><td/></tr><tr><td valign="top"> Male</td><td valign="bottom">n (%)</td><td valign="top">2 (50%)</td><td valign="top">0 (0%)</td><td valign="top">1 (25%)</td><td valign="top">1 (25%)</td></tr><tr><td valign="top"> Female</td><td valign="bottom">n (%)</td><td valign="top">2 (50%)</td><td valign="top">4 (100%)</td><td valign="top">3 (75%)</td><td valign="top">3 (75%)</td></tr><tr><td valign="top">Age</td><td valign="bottom">Mean (range)</td><td valign="top">24.5 (21&#8211;29)</td><td valign="top">24 (21&#8211;28)</td><td valign="top">21.5 (20&#8211;24)</td><td valign="top">22.5 (20&#8211;27)</td></tr><tr><td valign="top">BMI (<italic>kg/m<sup>2</sup></italic>)</td><td valign="bottom">Mean (range)</td><td valign="top">21 (18&#8211;23)</td><td valign="top">22 (19&#8211;25)</td><td valign="top">24.5 (21&#8211;27)</td><td valign="top">26.5 (24&#8211;29)</td></tr></tbody></table></table-wrap><br><h2><a href="https://github.com/elifesciences/elife-article-xml/tree/master/articles/elife-31549-v2.xml">elife-31549-v2.xml</a></h2><table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><label>Table 1.</label><caption><title>Baseline characteristics of the participants included in analysis.</title><p><supplementary-material id="table1sdata1"><label>Table 1&#8212;source data 1.</label><caption><title>Source data for <xref ref-type="table" rid="table1">Table 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-31549-table1-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th valign="top"/><th valign="top">LD-SP/SP</th><th valign="top">LD-SP/PIP</th><th valign="top">LD-PIP/PIP</th><th valign="top">LD-PIP/SP</th></tr></thead><tbody><tr><td valign="top">No. subjects</td><td valign="top"/><td valign="top">n&#160;=&#160;4</td><td valign="top">n&#160;=&#160;4</td><td valign="top">n&#160;=&#160;4</td><td valign="top">n&#160;=&#160;4</td></tr><tr><td valign="top">Treatment 1 (T1)</td><td/><td valign="top">Sulfadoxine-pyrimethamine 500 mg/25 mg</td><td valign="top">Sulfadoxine-pyrimethamine 500 mg/25 mg</td><td valign="top">Piperaquine 480 mg</td><td valign="top">Piperaquine 480 mg</td></tr><tr><td valign="top">Treatment 2 (T2)</td><td/><td valign="top">Sulfadoxine-pyrimethamine 1000 mg/50 mg</td><td valign="top">Piperaquine 960 mg</td><td valign="top">Piperaquine 960 mg</td><td valign="top">Sulfadoxine-pyrimethamine 1000 mg/50 mg</td></tr><tr><td valign="top">Sex</td><td/><td/><td/><td/><td/></tr><tr><td valign="top"> Male</td><td valign="bottom">n (%)</td><td valign="top">2 (50%)</td><td valign="top">0 (0%)</td><td valign="top">1 (25%)</td><td valign="top">1 (25%)</td></tr><tr><td valign="top"> Female</td><td valign="bottom">n (%)</td><td valign="top">2 (50%)</td><td valign="top">4 (100%)</td><td valign="top">3 (75%)</td><td valign="top">3 (75%)</td></tr><tr><td valign="top">Age</td><td valign="bottom">Mean (range)</td><td valign="top">24.5 (21&#8211;29)</td><td valign="top">24 (21&#8211;28)</td><td valign="top">21.5 (20&#8211;24)</td><td valign="top">22.5 (20&#8211;27)</td></tr><tr><td valign="top">BMI (<italic>kg/m<sup>2</sup></italic>)</td><td valign="bottom">Mean (range)</td><td valign="top">21 (18&#8211;23)</td><td valign="top">22 (19&#8211;25)</td><td valign="top">24.5 (21&#8211;27)</td><td valign="top">26.5 (24&#8211;29)</td></tr></tbody></table></table-wrap><br><h2><a href="https://github.com/elifesciences/elife-article-xml/tree/master/articles/elife-32506-v1.xml">elife-32506-v1.xml</a></h2><table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.32506.022</object-id><label>Table 1.</label><caption><title>Frequency of cell-intercalation events.</title><p><supplementary-material id="table1sdata1"><object-id pub-id-type="doi">10.7554/eLife.32506.023</object-id><label>Table 1-source data 1</label><caption><title>Source data for <xref ref-type="supplementary-material" rid="table1sdata1">Table 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32506-fig1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="2">Genotype <break/></th><th colspan="3">Frequency of intercalation (%)</th><th rowspan="2">n <break/></th></tr><tr valign="top"><th>Leftward</th><th>Rightward</th><th>Total</th></tr></thead><tbody><tr valign="top"><td>+/+</td><td>4.0</td><td>4.8</td><td>9.2*</td><td>250</td></tr><tr valign="top"><td><italic>Myo31DF</italic></td><td>2.2</td><td>3.3</td><td>6.0*</td><td>182</td></tr></tbody></table><table-wrap-foot><fn><p>Frequency is defined as the number of intercalation events divided by the total number of examined cells, in 30 min.</p><p>When two cells in a column had initial contact and were subsequently separated by another intervening cell, cell intercalation was said to occur, and the direction from which the intervening cell came was determined.</p></fn><fn><p>*includes one event that was not distinguished as leftward or rightward.</p></fn></table-wrap-foot></table-wrap><br><h2><a href="https://github.com/elifesciences/elife-article-xml/tree/master/articles/elife-44889-v2.xml">elife-44889-v2.xml</a></h2><table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.44889.016</object-id><label>Table 1.</label><caption><title>List of the 41 hit compounds that rescued the expression of both <italic>vcanb</italic> and <italic>mbp</italic> in <italic>adgrg6<sup>tb233c</sup></italic> mutants, thus representing putative Adgrg6 pathway modulators.</title><p>The table includes the plate and well ID, along with known activities and the average score from nine <italic>adgrg6<sup>tb233c</sup></italic> embryos in the <italic>vcanb</italic> assay, from six <italic>adgrg6<sup>tb233c</sup></italic> embryos in the <italic>mbp</italic> assay and from three <italic>adgrg6<sup>fr24</sup></italic> embryos in the <italic>fr24</italic> assay. Grey shading indicates compounds presumed to interact with Adgrg6 receptor directly; yellow shading indicates compounds presumed to be downstream effectors of the pathway. Abbreviations: DE, dead embryos; ND, no data; S, Spectrum; T, Tocris. *Note that cilnidipine can rescue <italic>fr24</italic> at 40 &#181;M (data not shown).&#160;See&#160;also&#160;<xref ref-type="supplementary-material" rid="table1sdata1">Table 1&#8212;source data 1</xref>.</p><p><supplementary-material id="table1sdata1"><object-id pub-id-type="doi">10.7554/eLife.44889.017</object-id><label>Table 1&#8212;source data 1.</label><caption><title>Source data for <xref ref-type="table" rid="table1">Table 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-44889-table1-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th>#</th><th>Plate</th><th>Well</th><th>Compound name</th><th>Known activity</th><th><italic>vcanb</italic> score</th><th><italic>mbp</italic> score</th><th><italic>fr24</italic> score</th></tr></thead><tbody><tr><td style="author-callout-style-b8">1</td><td style="author-callout-style-b8">S18</td><td style="author-callout-style-b8">C09</td><td style="author-callout-style-b8">CARAPIN-8(9)-ENE</td><td style="author-callout-style-b8">undetermined</td><td style="author-callout-style-b8">0.00</td><td style="author-callout-style-b8">8.50</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">2</td><td style="author-callout-style-b8">S25</td><td style="author-callout-style-b8">D08</td><td style="author-callout-style-b8">3-ISOBUTYL-1-METHYLXANTHINE (IBMX)</td><td style="author-callout-style-b8">phosphodiesterase inhibitor, non-selective adenosine receptor antagonist</td><td style="author-callout-style-b8">2.00</td><td style="author-callout-style-b8">8.50</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">3</td><td style="author-callout-style-b8">S17</td><td style="author-callout-style-b8">F05</td><td style="author-callout-style-b8">DEOXYGEDUNIN</td><td style="author-callout-style-b8">neuroprotective</td><td style="author-callout-style-b8">2.00</td><td style="author-callout-style-b8">8.00</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">4</td><td style="author-callout-style-b8">S23</td><td style="author-callout-style-b8">F10</td><td style="author-callout-style-b8">DIHYDROFISSINOLIDE</td><td style="author-callout-style-b8">undetermined</td><td style="author-callout-style-b8">2.67</td><td style="author-callout-style-b8">7.50</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">5</td><td style="author-callout-style-b8">S04</td><td style="author-callout-style-b8">B02</td><td style="author-callout-style-b8">IVERMECTIN</td><td style="author-callout-style-b8">antiparasitic</td><td style="author-callout-style-b8">2.33</td><td style="author-callout-style-b8">7.00</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">6</td><td style="author-callout-style-b8">T01</td><td style="author-callout-style-b8">F06</td><td style="author-callout-style-b8">SC-10</td><td style="author-callout-style-b8">protein kinase C activator, NMDA receptor activator</td><td style="author-callout-style-b8">5.67</td><td style="author-callout-style-b8">6.50</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">7</td><td style="author-callout-style-b8">T01</td><td style="author-callout-style-b8">H11</td><td style="author-callout-style-b8">1,3-Dipropyl-8-phenylxanthine</td><td style="author-callout-style-b8">Selective adenosine A1 receptor antagonist</td><td style="author-callout-style-b8">3.33</td><td style="author-callout-style-b8">6.50</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">8</td><td style="author-callout-style-b8">S17</td><td style="author-callout-style-b8">E02</td><td style="author-callout-style-b8">3-DEOXO-3beta-ACETOXYDEOXYDIHYDROGEDUNIN</td><td style="author-callout-style-b8">undetermined</td><td style="author-callout-style-b8">0.00</td><td style="author-callout-style-b8">6.50</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">9</td><td style="author-callout-style-b8">T11</td><td style="author-callout-style-b8">F07</td><td style="author-callout-style-b8">Cilnidipine*</td><td style="author-callout-style-b8">dihydropyridine N- and L-type Ca<sup>2+</sup> channel blocker</td><td style="author-callout-style-b8">2.00</td><td style="author-callout-style-b8">6.50</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">10</td><td style="author-callout-style-b8">S13</td><td style="author-callout-style-b8">F03</td><td style="author-callout-style-b8">AMIODARONE HYDROCHLORIDE</td><td style="author-callout-style-b8">coronary vasodilator, Ca<sup>2+</sup> channel blocker</td><td style="author-callout-style-b8">5.00</td><td style="author-callout-style-b8">6.50</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">11</td><td style="author-callout-style-b8">S06</td><td style="author-callout-style-b8">E02</td><td style="author-callout-style-b8">HYDROCORTISONE HEMISUCCINATE</td><td style="author-callout-style-b8">glucocorticoid</td><td style="author-callout-style-b8">3.67</td><td style="author-callout-style-b8">6.00</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">12</td><td style="author-callout-style-b8">T01</td><td style="author-callout-style-b8">C04</td><td style="author-callout-style-b8">(RS)-(Tetrazol-5-yl)glycine</td><td style="author-callout-style-b8">highly potent NMDA receptor agonist</td><td style="author-callout-style-b8">3.00</td><td style="author-callout-style-b8">5.00</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">13</td><td style="author-callout-style-b8">S02</td><td style="author-callout-style-b8">E05</td><td style="author-callout-style-b8">LOMEFLOXACIN HYDROCHLORIDE</td><td style="author-callout-style-b8">antibacterial</td><td style="author-callout-style-b8">5.33</td><td style="author-callout-style-b8">5.00</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">14</td><td style="author-callout-style-b8">S13</td><td style="author-callout-style-b8">E04</td><td style="author-callout-style-b8">ETHAMIVAN</td><td style="author-callout-style-b8">CNS &amp; respiratory stimulant</td><td style="author-callout-style-b8">4.67</td><td style="author-callout-style-b8">5.00</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">15</td><td style="author-callout-style-b8">T08</td><td style="author-callout-style-b8">B04</td><td style="author-callout-style-b8">CGS 15943</td><td style="author-callout-style-b8">potent adenosine receptor antagonist</td><td style="author-callout-style-b8">5.33</td><td style="author-callout-style-b8">4.50</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">16</td><td style="author-callout-style-b8">S13</td><td style="author-callout-style-b8">E09</td><td style="author-callout-style-b8">ASTEMIZOLE</td><td style="author-callout-style-b8">H1 antihistamine (nonsedating)</td><td style="author-callout-style-b8">4.67</td><td style="author-callout-style-b8">4.50</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">17</td><td style="author-callout-style-b8">T02</td><td style="author-callout-style-b8">A09</td><td style="author-callout-style-b8">SKF 91488 dihydrochloride</td><td style="author-callout-style-b8">histamine N-methyltransferase inhibitor</td><td style="author-callout-style-b8">3.00</td><td style="author-callout-style-b8">4.00</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">18</td><td style="author-callout-style-b8">S25</td><td style="author-callout-style-b8">F05</td><td style="author-callout-style-b8">11alpha-HYDROXYPROGESTERONE HEMISUCCINATE</td><td style="author-callout-style-b8">glucocorticoid</td><td style="author-callout-style-b8">2.67</td><td style="author-callout-style-b8">4.00</td><td style="author-callout-style-b8">9.00</td></tr><tr><td style="author-callout-style-b8">19</td><td style="author-callout-style-b8">T14</td><td style="author-callout-style-b8">A07</td><td style="author-callout-style-b8">Efonidipine hydrochloride monoethanolate</td><td style="author-callout-style-b8">dihydropyridine L-type and T-type Ca<sup>2+</sup> channel blocker</td><td style="author-callout-style-b8">3.67</td><td style="author-callout-style-b8">4.00</td><td style="author-callout-style-b8">9.00</td></tr><tr><td>20</td><td>T05</td><td>C09</td><td>Nifedipine</td><td>dihydropyridine L-type Ca<sup>2+</sup> channel blocker</td><td>4.33</td><td>7.00</td><td>8.00</td></tr><tr><td>21</td><td>T05</td><td>E08</td><td>CGP 37157</td><td>antagonist of mitochondrial Na<sup>+</sup>/Ca<sup>2+</sup> exchange</td><td>3.67</td><td>6.50</td><td>8.00</td></tr><tr><td>22</td><td>S05</td><td>D03</td><td>DANAZOL</td><td>anterior pituitary suppressant, anti-estrogenic</td><td>1.00</td><td>5.00</td><td>8.00</td></tr><tr><td>23</td><td>S18</td><td>H09</td><td>XANTHYLETIN</td><td>undetermined</td><td>1.00</td><td>4.50</td><td>8.00</td></tr><tr><td>24</td><td>S18</td><td>A06</td><td>FERULIC ACID</td><td>antineoplastic, choleretic, food preservative</td><td>3.67</td><td>4.00</td><td>8.00</td></tr><tr><td>25</td><td>S18</td><td>F02</td><td>alpha-DIHYDROGEDUNOL</td><td>undetermined</td><td>2.33</td><td>4.00</td><td>8.00</td></tr><tr><td style="author-callout-style-b4">26</td><td style="author-callout-style-b4">T05</td><td style="author-callout-style-b4">F04</td><td style="author-callout-style-b4">(S)-(+)-Niguldipine hydrochloride</td><td style="author-callout-style-b4">dihydropyridine L-type Ca<sup>2+</sup> channel blocker, &#945;1 antagonist</td><td style="author-callout-style-b4">3.67</td><td style="author-callout-style-b4">5.00</td><td style="author-callout-style-b4">7.00</td></tr><tr><td style="author-callout-style-b4">27</td><td style="author-callout-style-b4">T07</td><td style="author-callout-style-b4">F02</td><td style="author-callout-style-b4">Tracazolate hydrochloride</td><td style="author-callout-style-b4">subtype-selective GABA<sub>A</sub>allosteric modulator</td><td style="author-callout-style-b4">2.33</td><td style="author-callout-style-b4">4.50</td><td style="author-callout-style-b4">7.00</td></tr><tr><td style="author-callout-style-b4">28</td><td style="author-callout-style-b4">S10</td><td style="author-callout-style-b4">E02</td><td style="author-callout-style-b4">NIMODIPINE</td><td style="author-callout-style-b4">dihydropyridine L-type Ca<sup>2+</sup> channel blocker</td><td style="author-callout-style-b4">0.33</td><td style="author-callout-style-b4">7.00</td><td style="author-callout-style-b4">6.00</td></tr><tr><td style="author-callout-style-b4">29</td><td style="author-callout-style-b4">S17</td><td style="author-callout-style-b4">E06</td><td style="author-callout-style-b4">3beta-ACETOXYDEOXODIHYDROGEDUNIN</td><td style="author-callout-style-b4">undetermined</td><td style="author-callout-style-b4">2.00</td><td style="author-callout-style-b4">4.50</td><td style="author-callout-style-b4">5.00</td></tr><tr><td style="author-callout-style-b4">30</td><td style="author-callout-style-b4">S17</td><td style="author-callout-style-b4">F02</td><td style="author-callout-style-b4">DIHYDROGEDUNIN</td><td style="author-callout-style-b4">undetermined</td><td style="author-callout-style-b4">1.67</td><td style="author-callout-style-b4">5.00</td><td style="author-callout-style-b4">2.00</td></tr><tr><td style="author-callout-style-b4">31</td><td style="author-callout-style-b4">S22</td><td style="author-callout-style-b4">F09</td><td style="author-callout-style-b4">TANGERITIN</td><td style="author-callout-style-b4">undetermined</td><td style="author-callout-style-b4">1.33</td><td style="author-callout-style-b4">5.50</td><td style="author-callout-style-b4">1.00</td></tr><tr><td style="author-callout-style-b4">32</td><td style="author-callout-style-b4">S10</td><td style="author-callout-style-b4">F07</td><td style="author-callout-style-b4">COLFORSIN</td><td style="author-callout-style-b4">adenylate cyclase activator, antiglaucoma, hypotensive, vasodilator</td><td style="author-callout-style-b4">0.00</td><td style="author-callout-style-b4">9.00</td><td style="author-callout-style-b4">0.00</td></tr><tr><td>33</td><td>T04</td><td>G02</td><td>Imiloxan hydrochloride</td><td>selective &#945;<sub>2B</sub>-adrenoceptor antagonist</td><td>0.67</td><td>9.00</td><td>ND</td></tr><tr><td>34</td><td>S24</td><td>C03</td><td>3alpha-ACETOXYDIHYDRODEOXYGEDUNIN</td><td>undetermined</td><td>0.33</td><td>8.50</td><td>DE</td></tr><tr><td style="author-callout-style-b4">35</td><td style="author-callout-style-b4">S11</td><td style="author-callout-style-b4">E02</td><td style="author-callout-style-b4">EZETIMIBE</td><td style="author-callout-style-b4">antihyperlipidemic (sterol absorption inhibitor)</td><td style="author-callout-style-b4">2.00</td><td style="author-callout-style-b4">7.50</td><td style="author-callout-style-b4">0.00</td></tr><tr><td>36</td><td>S10</td><td>E06</td><td>NITRENDIPINE</td><td>dihydropyridine L-type Ca<sup>2+</sup> channel blocker</td><td>1.33</td><td>7.00</td><td>ND</td></tr><tr><td style="author-callout-style-b4">37</td><td style="author-callout-style-b4">S11</td><td style="author-callout-style-b4">E08</td><td style="author-callout-style-b4">ROSUVASTATIN CALCIUM</td><td style="author-callout-style-b4">antihyperlipidemic</td><td style="author-callout-style-b4">0.00</td><td style="author-callout-style-b4">6.00</td><td style="author-callout-style-b4">0.00</td></tr><tr><td style="author-callout-style-b4">38</td><td style="author-callout-style-b4">S22</td><td style="author-callout-style-b4">C07</td><td style="author-callout-style-b4">DEMETHYLNOBILETIN</td><td style="author-callout-style-b4">undetermined</td><td style="author-callout-style-b4">0.00</td><td style="author-callout-style-b4">6.00</td><td style="author-callout-style-b4">0.00</td></tr><tr><td>39</td><td>S22</td><td>G11</td><td>HEXAMETHYLQUERCETAGETIN</td><td>undetermined</td><td>0.00</td><td>5.50</td><td>DE</td></tr><tr><td>40</td><td>S22</td><td>F08</td><td>NOBILETIN</td><td>matrix metaloproteinase inhibitor, antineoplastic, anti-ERK, NF-&#954;B suppressor</td><td>0.00</td><td>5.00</td><td>DE</td></tr><tr><td>41</td><td>S12</td><td>H07</td><td>PREGNENOLONE SUCCINATE</td><td>glucocortcoid, antiinflammatory</td><td>4.67</td><td>4.00</td><td>DE</td></tr></tbody></table></table-wrap><br><h2><a href="https://github.com/elifesciences/elife-article-xml/tree/master/articles/elife-54275-v1.xml">elife-54275-v1.xml</a></h2><table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><label>Table 1.</label><caption><title>Comparison of parameters between orexin neuron-ablated mice and orexin MCH-blated mice.</title><p><supplementary-material id="table1sdata1"><label>Table 1&#8212;source data 1.</label><caption><title>Source&#160;data&#160;for&#160;<xref ref-type="table" rid="table1">Table 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54275-table1-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Parameter</th><th valign="top">Orexin neuron-ablated mice</th><th valign="top">Orexin and MCH-ablated mice</th><th valign="top">- fold Difference (OXMC/OX)</th><th valign="top"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top">Earliest detection timing of cataplexy</td><td valign="top">2 weeks post-ablation</td><td valign="top">2 weeks post-ablation</td><td valign="top">N/A</td><td valign="top">N/A</td></tr><tr><td valign="top">Time-of-day occurrence at 4 weeks</td><td valign="top">Both light and dark phases</td><td valign="top">Both light and dark phases</td><td valign="top">N/A</td><td valign="top">N/A</td></tr><tr><td valign="top">Total time in wakefulness during dark phase at 4 weeks</td><td valign="top">418.9&#160;&#177;&#160;20.2 min</td><td valign="top">571.0&#160;&#177;&#160;22.2 min</td><td valign="top">1.36</td><td valign="top">1.4E-03</td></tr><tr><td valign="top">Total time in NREM sleep during dark phase at 4 weeks</td><td valign="top">258.3&#160;&#177;&#160;16.2 min</td><td valign="top">90.5&#160;&#177;&#160;19.8 min</td><td valign="top">0.35</td><td valign="top">2.8E-04</td></tr><tr><td valign="top">Total time in REM sleep during dark phase at 4 weeks</td><td valign="top">25.6&#160;&#177;&#160;0.9 min</td><td valign="top">2.7&#160;&#177;&#160;1.7 min</td><td valign="top">0.10</td><td valign="top">4.3E-06</td></tr><tr><td valign="top">Total time in wakefulness during light phase at 4 weeks</td><td valign="top">278.1&#160;&#177;&#160;19.7 min</td><td valign="top">322.6&#160;&#177;&#160;7.3 min</td><td valign="top">1.16</td><td valign="top">3.1E-02</td></tr><tr><td valign="top">Total time in NREM sleep during light phase at 4 weeks</td><td valign="top">389.8&#160;&#177;&#160;17.4 min</td><td valign="top">340.1&#160;&#177;&#160;8.1 min</td><td valign="top">0.87</td><td valign="top">1.6E-02</td></tr><tr><td valign="top">Total time in REM sleep during light phase at 4 weeks</td><td valign="top">46.3&#160;&#177;&#160;3.4 min</td><td valign="top">20.8&#160;&#177;&#160;4.2 min</td><td valign="top">0.45</td><td valign="top">2.7E-03</td></tr><tr><td valign="top">Total time in cataplexy in dark phase at 4 weeks</td><td valign="top">11.0&#160;&#177;&#160;0.6 min</td><td valign="top">31.2&#160;&#177;&#160;3.6 min</td><td valign="top">2.83</td><td valign="top">2.6E-03</td></tr><tr><td valign="top">Number of cataplexy bouts in dark phase at 4 weeks</td><td valign="top">14.8&#160;&#177;&#160;2.0</td><td valign="top">16.9&#160;&#177;&#160;2.1</td><td valign="top">1.14</td><td valign="top">0.53</td></tr><tr><td valign="top">Mean bout duration in dark phase at 4 weeks</td><td valign="top">53.3&#160;&#177;&#160;7.6 sec</td><td valign="top">113.0&#160;&#177;&#160;9.6 sec</td><td valign="top">2.12</td><td valign="top">2.2E-03</td></tr><tr><td valign="top">Total time in cataplexy in light phase at 4 weeks</td><td valign="top">5.4&#160;&#177;&#160;0.9 min</td><td valign="top">24.2&#160;&#177;&#160;4.5 min</td><td valign="top">4.45</td><td valign="top">1.4E-02</td></tr><tr><td valign="top">Number of cataplexy bouts in light phase at 4 weeks</td><td valign="top">8.3&#160;&#177;&#160;1.4</td><td valign="top">15.4&#160;&#177;&#160;3.1</td><td valign="top">1.87</td><td valign="top">0.13</td></tr><tr><td valign="top">Mean bout duration in light phase at 4 weeks</td><td valign="top">50.0&#160;&#177;&#160;11.4 sec</td><td valign="top">96.3&#160;&#177;&#160;4.8 sec</td><td valign="top">1.93</td><td valign="top">1.7E-03</td></tr></tbody></table></table-wrap>
            </body>
        </html>
    